Citi tells investors it’s time to sell Moderna after 600%-plus stock gains

Citi analysts have downgraded Moderna, telling investors that the stock's more than 600% gain has outpaced what revenue and profit forecasts can reasonably support. In their view, the share price now embeds expectations that go beyond what the company's projected financials justify — a classic case of valuation running ahead of fundamentals.

The call matters because it highlights a tension that often emerges after a dramatic rally: momentum can carry a stock well past the point where earnings estimates provide a valuation anchor. When analysts flag that gap, it can prompt investors to reassess what they are paying for future growth, particularly for a company whose results depend on a small number of products and uncertain long-term demand.

What to watch from here is whether other analysts revise their own estimates or price targets, and whether upcoming quarterly results and guidance validate or challenge Citi's caution. For now, the debate is less about Moderna's business than about the price investors are willing to pay for it.